Jeffrey Engelman

Jeff Engelman is the co-founder and Chief Scientific Officer of Treeline Biosciences. Previously, he was the Vice President and Global Head of Oncology at the Novartis Institutes for BioMedical Research, where he directed cancer drug discovery. Prior to Novartis, Dr. Engelman was Director of the Center for Thoracic Oncology and Molecular Therapeutic at Massachusetts General Hospital, where he studied responses to targeted therapies and mechanisms of resistance in lung cancer. He was also an Associate Professor at Harvard Medical School. Dr. Engelman received his B.A. in Chemistry from Northwestern University and his M.D. and Ph.D. from the Albert Einstein College of Medicine. He completed residency training in Internal Medicine at Brigham and Women's Hospital, a fellowship in Hematology/Oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital, and postdoctoral research in the laboratory of Professor Lewis Cantley at Beth Israel Deaconess Medical Center.